Shows reduced RSV-related cases in infants, highlighting nirsevimab's effectiveness.
After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%-70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV-associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: